Weichen Hou^*, Lei Song^†, Yang Zhao^*, Qun Liu^*, Shuyan Zhang^‡

Oncology Research, Vol.28, No.7-8, pp. 815-818, 2020, DOI:10.3727/096504021X16240202939988

Abstract The role of miRNAs in the radiosensitivity of glioma cells and the underlying mechanism is still far from clear. In the present study, we detected six downregulated and seven upregulated miRNAs in the serum after radiotherapy compared with paired serum samples before radiotherapy via miRNA panel PCR. Among these, miR-17-5p was highly reduced (fold change = −4.21). Further, we validated the levels of miR-17-5p in all serum samples with qRT-PCR. In addition, statistical analysis suggested that a reduced miR-17-5P level was positively associated with advanced clinical stage of glioma, incidence of relapse, and tumor differentiation. Moreover, we provided evidence that… More >

Arisha Patel, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic Farah, Robert L. Redner, Annie Im, Kathleen A. Dorritie, Alison Sehgal, James Rossetti, Melissa Saul, Daniel Normolle, Konstantinos Lontos, Michael Boyiadzis

Oncology Research, Vol.28, No.7-8, pp. 811-814, 2020, DOI:10.3727/096504020X15965357399750

Abstract Leukemia relapse 5 years after achieving first complete remission (CR1) is uncommon in patients with acute myeloid leukemia (AML). In this study, we evaluated the outcomes of AML patients with late relapse at our institution and reviewed the literature for these patients. The study cohort consisted of nine AML patients with late relapse. The median interval between CR1 and AML relapse was 6.1 years (range: 5.1–16.2 years). At relapse, the karyotype was different from the initial AML diagnosis in 50% of patients. At the time of AML relapse, seven patients received induction chemotherapy and two patients received hypomethylating agents with… More >

Tsung-Kun Chang^*†, Tzu-Chieh Yin^‡§, Wei-Chih Su^*†, Hsiang-Lin Tsai^*¶, Ching-Wen Huang^*¶, Yen-Cheng Chen^*, Ching-Chun Li^*, Po-Jung Chen^*, Cheng-Jen Ma^*§, Kuo-Hsiang Chuang^#, Tian-Lu Cheng^**, Jaw-Yuan Wang^{*†¶††‡‡§§}

Oncology Research, Vol.28, No.7-8, pp. 801-809, 2020, DOI:10.3727/096504021X16218531628569

Abstract Irinotecan, a topoisomerase inhibitor, is a common cytotoxic agent prescribed for metastatic colorectal cancer (mCRC) patients. Diarrhea is the most common adverse event (AE). The underlying mechanism of irinotecaninduced diarrhea is intestinal mucosal damage caused by SN-38 (active metabolite of irinotecan) hydrolyzed from SN-38G (inactive metabolite) by bacterial -glucuronidase ( G). According to an animal study, silymarin reduces the activity of bacterial G without impairing antitumor efficacy. We conducted a prospective openlabel pilot study to evaluate the effect of silymarin as supplementation in reducing toxicities of mCRC patients undergoing irinotecan-based chemotherapy. We enrolled and randomized 70 mCRC patients receiving first-line… More >

Chunmou Li^*1, Xiaomin Peng^*1, Chuchu Feng^*1, Xilin Xiong^*, Jianxin Li^†, Ning Liao^‡, Zhen Yang^§, Aiguo Liu^¶, Pingping Wu^*, Xuehong Liang^†, Yunyan He^‡, Xin Tian^§, Yunbi Lin^§, Songmi Wang^¶, Yang Li^*

Oncology Research, Vol.28, No.7-8, pp. 791-800, 2020, DOI:10.3727/096504021X16184815905096

Abstract This nonrandomized, multicenter cohort, open-label clinical trial evaluated the efficacy and safety of combined chemotherapy with arsenic trioxide (ATO) in children with stage 4/M neuroblastoma (NB). We enrolled patients who were newly diagnosed with NB and assessed as stage 4/M and received either traditional chemotherapy or ATO combined with chemotherapy according to their own wishes. Twenty-two patients were enrolled in the trial group (ATO combined with chemotherapy), and 13 patients were enrolled in the control group (traditional chemotherapy). Objective response rate (ORR) at 4 weeks after completing induction chemotherapy was defined as the main outcome, and adverse events were monitored… More >

Sarah A. Scuderi^*, Marika Lanza^*, Giovanna Casili^*, Francesca Esposito^†, Cristina Colarossi^‡, Dario Giuffrida^‡, Paterniti Irene^*, Salvatore Cuzzocrea^*,* Emanuela Esposito^*, Michela Campolo^*

Oncology Research, Vol.28, No.7-8, pp. 779-790, 2020, DOI:10.3727/096504021X16161478258040

Abstract Glioma are common malignant brain tumors, among which glioblastoma multiforme (GBM) has the worst prognosis. Different studies of GBM revealed that targeting nuclear factor B (NF- B) induced an attenuation tumor proliferation and prolonged cell survival. TBK1 {TANK [TRAF (TNF (tumor-necrosis-factor) receptorassociated factor)-associated NF- B activator]-binding kinase 1} is a serine/threonine protein kinase, and it is a member of the I B kinase (IKK) family involved in NF- B pathway activation. The aim of this study was to investigate the potential effect of BX795, an inhibitor of TBK1, in an in vitro and ex vivo model of GBM. GBM cell… More >

Hongde Li^*†‡, Yueshuo Li^*†‡, Jianmin Hu^*†‡, Sufang Liu^§, Xiangjian Luo^*†‡¶, Min Tang^*†‡, Ann M. Bode^#, Zigang Dong^#**, Xinqi Liu^††, Weihua Liao^‡‡, Ya Cao^{*†‡¶ §§¶¶}

Oncology Research, Vol.28, No.7-8, pp. 763-778, 2020, DOI:10.3727/096504021X16135618512563

Abstract Epstein–Barr virus (EBV)-encoded latent membrane protein 1 (LMP1) plays an important oncogenic role in the viral latent infection. Recently, increasing evidence indicates that the high expression of LMP1 during EBV lytic cycle is related to the viral lytic replication. However, the mechanism by which LMP1 regulates EBV lytic replication remains unclear. (−)-Epigallocatechin-3-gallate (EGCG) prevents carcinogenesis by directly targeting numerous membrane proteins and effectively inhibits EBV lytic cascade. Here, we demonstrated that LMP1 promotes EBV lytic replication through the downstream signal molecules MAPKs, including ERKs, p38, and JNKs. LMP1 induces the phosphorylation of p53 through MAPKs to enhance the ability of… More >

Huan Ma¹, Cong Nie¹, Ying Chen, Jinmiao Li, Yanjie Xie, Zhixin Tang, Yang Gao, Siming Ai, Yuxiang Mao, Qian Sun, Rong Lu

Oncology Research, Vol.28, No.7-8, pp. 745-761, 2020, DOI:10.3727/096504021X16130322409507

Abstract Cell cycle deregulation is involved in the pathogenesis of many cancers and is often associated with protein kinase aberrations, including the polo-like kinase 1 (PLK1). We used retinoblastoma, an intraocular malignancy that lacks targeted therapy, as a disease model and set out to reveal targetability of PLK1 with a small molecular inhibitor ON-01910.Na. First, transcriptomic analysis on patient retinoblastoma tissues suggested that cell cycle progression was deregulated and confirmed that PLK1 pathway was upregulated. Next, antitumor activity of ON-01910.Na was investigated in both cellular and animal levels. Cytotoxicity induced by ON-01910.Na was tumor specific and dose dependent in retinoblastoma cells,… More >

Huiling Wang^*, Xin Hu^†, Feng Yang^‡, Hui Xiao^*

Oncology Research, Vol.28, No.7-8, pp. 731-744, 2020, DOI:10.3727/096504020X16100888208039

Abstract This study was designed to investigate the precise mechanisms of miR-325-3p/S100A2 axis in breast cancer (BC). In this study, we found that the level of miR-325-3p was dramatically increased in BC tissues and cell lines, and the expression of S100A2 was significantly decreased. Also, the high level of miR-325-3p was closely associated with low expression of S100A2 in BC tissues. Moreover, introduction of miR-325-3p significantly promoted proliferation, invasion, and EMT of BC cells. Bioinformatics analysis predicted that the S100A2 was a potential target gene of miR-325-3p. Luciferase reporter assay demonstrated that miR-325-3p could directly target S100A2. In addition, miR-325-3p overexpression… More >

Pihua Han^*†1, Haiming Yang^‡1, Xiang Li^*1, Jie Wu^*, Peili Wang^§, Dapeng Liu^*, Guodong Xiao^¶, Xin Sun^*, Hong Ren^*

Oncology Research, Vol.28, No.7-8, pp. 715-729, 2020, DOI:10.3727/096504020X16037124605559

Abstract The aim of this study was to identify a novel cancer stemness-related ceRNA regulatory axis in lung adenocarcinoma (LUAD) via weighted gene coexpression network analysis of a stemness index. The RNA sequencing expression profiles of 513 cancer samples and 60 normal samples were obtained from the TCGA database. Differentially expressed mRNAs (DEmRNAs), lncRNAs (DElncRNAs), and miRNAs (DEmiRNAs) were identified with R software. Functional enrichment analysis was conducted using DAVID 6.8. The ceRNA network was constructed via multiple bioinformatics analyses, and the correlations between possible ceRNAs and prognosis were analyzed using Kaplan–Meier plots. WGCNA was then applied to distinguish key genes… More >

Ching-Wen Huang^*, Cheng-Jen Ma^*†, Wei-Chih Su^*, Yi-Ting Chen^‡§, Hsiang-Lin Tsai^*¶, Yung-Sung Yeh^*#, Tsung-Kun Chang^*, Wen-Hung Hsu^**††, Fang-Jung Yu^**††, Jaw-Yuan Wang^{*¶‡‡§§¶¶##}

Oncology Research, Vol.28, No.7-8, pp. 701-714, 2020, DOI:10.3727/096504020X15986099915822

Abstract This study evaluated the survival effects of metronomic maintenance therapy with oral fluoropyrimidine in patients with stage III colorectal cancer (CRC) according to epidermal growth factor receptor (EGFR) expression. We enrolled 197 patients with stage III CRC who had undergone radical resection and FOLFOX regimen adjuvant chemotherapy. The clinicopathological features and effects of metronomic maintenance therapy with oral capecitabine (daily dose of 850 mg/m2 , twice daily, on days 1–14 every 3 weeks for 6 months) on survival according to treatment group and EGFR expression were analyzed. By conducting an in vitro cell line study and in vivo study through… More >